Huonslab is a clinical-stage biopharmaceutical company
with Biologics Sub-Q Delivery Platform, 
DIFFerentiated Hyaluronidase for Biologics
Sub-Q Delivery Platform
Our lead program, HLB3-002 is a highly Purified recombinant human hyaluronidase (HyDIFFUZE)
based drug product that would replace animal testes-derived hyaluronidases on the market.
It is being currently developed at IND-stage and a large pivotal P1 is planned to start in Q3 2024.
Webinar at Huonslab is a Knowledge Platform on Hyaluronidase based Biologics
Sub-Q Delivery led by industry experts in each specific field :
- QSP(Quantitative Systems Pharmacology) on rHuPH20
- Human Interactome Hyaluronidase : Protein-Protein Interaction of rHuPH20
- SC Antibody-rHuPH20 model-based PK predictions : Optimization of SC dose & regimens for new innovative Antibodies-HyDIFFUZE co-formulations
- Bio-physico-chemical properties of antibodies under development
- SC HD/HV/LM Biologics Formulation Development Boundaries & Obstacles
- Regulatory framework for US & EU: List and Scope of HyDIFFUZE regulatory documents for co-formulations
We are dedicated to
advancing Biologics R&D
and Sub-Q Delivery innovation
with a pioneering spirit.
Huonslab was established in 2018 with a mission to innovate in the human
hyaluronidase-based biologics Sub-Q delivery field. Delivering high-dose,
high-volume antibodies Sub-Q is challenging, but our scientists at Huonslab
are pushing the boundaries and advancing toward making every antibody
Sub-Q deliverable in a timely manner.
